These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8597745)

  • 1. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.
    Anderson KE; Girdwood AC; Wilson JA
    BMJ; 1996 Mar; 312(7032):702; author reply 704-5. PubMed ID: 8597745
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages.
    MacMahon DG; Bland R
    BMJ; 1996 Mar; 312(7032):703; author reply 704-5. PubMed ID: 8597748
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
    Olanow CW; Godbold JH; Koller W
    BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.
    Yu PH; Lai CT; Boulton AA
    BMJ; 1996 Mar; 312(7032):703-4; author reply 704-5. PubMed ID: 8597749
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used.
    Gerlach M; Riederer P; Vogt H
    BMJ; 1996 Mar; 312(7032):704; author reply 704-5. PubMed ID: 8597750
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.
    Jellinger KA
    BMJ; 1996 Mar; 312(7032):704-5. PubMed ID: 8597751
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality.
    Mäki-Ikola O; Kilkku O; Heinonen E
    BMJ; 1996 Mar; 312(7032):702; author reply 704-5. PubMed ID: 8597744
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.
    Silva MT; Watts PM; Jenner P
    BMJ; 1996 Mar; 312(7032):703; author reply 704-5. PubMed ID: 8597747
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 12. Mortality associated with selegiline in Parkinson's disease. What do the available data mean?
    Mizuno Y; Kondo T
    Drug Saf; 1997 May; 16(5):289-94. PubMed ID: 9187529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline and excess mortality.
    Oakes D
    Clin Neuropharmacol; 1997 Dec; 20(6):542. PubMed ID: 9403228
    [No Abstract]   [Full Text] [Related]  

  • 14. Strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Coyle J; Hobson P; Meara J
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280; author reply 281-2. PubMed ID: 9703194
    [No Abstract]   [Full Text] [Related]  

  • 18. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Heinonen E; Myllylä V
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280-2. PubMed ID: 9703195
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline in Parkinson's disease.
    Calne DB
    BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.